Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more
Photocure ASA (PHCUF) - Net Assets
Latest net assets as of September 2025: $484.54 Million USD
Based on the latest financial reports, Photocure ASA (PHCUF) has net assets worth $484.54 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($693.75 Million) and total liabilities ($209.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $484.54 Million |
| % of Total Assets | 69.84% |
| Annual Growth Rate | 5.13% |
| 5-Year Change | -1.26% |
| 10-Year Change | 138.84% |
| Growth Volatility | 126.47 |
Photocure ASA - Net Assets Trend (2002–2024)
This chart illustrates how Photocure ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Photocure ASA (2002–2024)
The table below shows the annual net assets of Photocure ASA from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $501.72 Million | +3.91% |
| 2023-12-31 | $482.85 Million | +4.35% |
| 2022-12-31 | $462.73 Million | -7.94% |
| 2021-12-31 | $502.63 Million | -1.08% |
| 2020-12-31 | $508.13 Million | +143.60% |
| 2019-12-31 | $208.59 Million | +18.29% |
| 2018-12-31 | $176.34 Million | -19.14% |
| 2017-12-31 | $218.08 Million | -13.44% |
| 2016-12-31 | $251.94 Million | +19.94% |
| 2015-12-31 | $210.06 Million | -12.50% |
| 2014-12-31 | $240.06 Million | -10.80% |
| 2013-12-31 | $269.12 Million | -29.23% |
| 2012-12-31 | $380.27 Million | -13.45% |
| 2011-12-31 | $439.34 Million | -4.25% |
| 2010-12-31 | $458.85 Million | +10.36% |
| 2009-12-31 | $415.78 Million | +108.21% |
| 2008-12-31 | $199.69 Million | -23.19% |
| 2007-12-31 | $259.99 Million | -20.48% |
| 2006-12-31 | $326.94 Million | +574.58% |
| 2005-12-31 | $48.47 Million | -43.36% |
| 2004-12-31 | $85.57 Million | -35.13% |
| 2003-12-31 | $131.90 Million | -21.02% |
| 2002-12-31 | $167.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Photocure ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 91.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $9.14 Million | 1.83% |
| Common Stock | $13.56 Million | 2.71% |
| Other Comprehensive Income | $4.34 Million | 0.87% |
| Other Components | $473.21 Million | 94.59% |
| Total Equity | $500.25 Million | 100.00% |
Photocure ASA Competitors by Market Cap
The table below lists competitors of Photocure ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Quang Viet Enterprise Co Ltd
TW:4438
|
$86.16 Million |
|
Galaxy Software Services Corporation
TWO:6752
|
$86.18 Million |
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
$86.19 Million |
|
Samhwa Paint
KO:000390
|
$86.24 Million |
|
Discovery Holdings Ltd
JSE:DSY
|
$86.12 Million |
|
Sanderson Design Group plc
PINK:WKGBF
|
$86.12 Million |
|
Nepes Ark Corp.
KQ:330860
|
$86.12 Million |
|
Semperit Aktiengesellschaft Holding
PINK:SEIGF
|
$86.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Photocure ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 482,848,000 to 500,247,000, a change of 17,399,000 (3.6%).
- Net loss of 4,810,000 reduced equity.
- Other comprehensive income increased equity by 4,335,999.
- Other factors increased equity by 17,873,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.81 Million | -0.96% |
| Other Comprehensive Income | $4.34 Million | +0.87% |
| Other Changes | $17.87 Million | +3.57% |
| Total Change | $- | 3.60% |
Book Value vs Market Value Analysis
This analysis compares Photocure ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.45x to 0.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $9.59 | $4.32 | x |
| 2003-12-31 | $7.48 | $4.32 | x |
| 2004-12-31 | $4.86 | $4.32 | x |
| 2005-12-31 | $2.75 | $4.32 | x |
| 2006-12-31 | $15.30 | $4.32 | x |
| 2007-12-31 | $11.70 | $4.32 | x |
| 2008-12-31 | $9.04 | $4.32 | x |
| 2009-12-31 | $18.82 | $4.32 | x |
| 2010-12-31 | $20.99 | $4.32 | x |
| 2011-12-31 | $20.39 | $4.32 | x |
| 2012-12-31 | $17.81 | $4.32 | x |
| 2013-12-31 | $12.63 | $4.32 | x |
| 2014-12-31 | $11.25 | $4.32 | x |
| 2015-12-31 | $9.78 | $4.32 | x |
| 2016-12-31 | $11.70 | $4.32 | x |
| 2017-12-31 | $10.12 | $4.32 | x |
| 2018-12-31 | $8.15 | $4.32 | x |
| 2019-12-31 | $9.55 | $4.32 | x |
| 2020-12-31 | $20.64 | $4.32 | x |
| 2021-12-31 | $18.72 | $4.32 | x |
| 2022-12-31 | $17.12 | $4.32 | x |
| 2023-12-31 | $17.80 | $4.32 | x |
| 2024-12-31 | $18.45 | $4.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Photocure ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.92%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.48x
- Recent ROE (-0.96%) is above the historical average (-11.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -57.49% | -380.62% | 0.08x | 1.79x | $-112.70 Million |
| 2003 | -32.65% | -77.54% | 0.24x | 1.78x | $-55.87 Million |
| 2004 | -52.73% | -57.87% | 0.45x | 2.03x | $-53.57 Million |
| 2005 | -78.84% | -71.23% | 0.51x | 2.18x | $-43.06 Million |
| 2006 | 26.02% | 40.45% | 0.56x | 1.15x | $52.39 Million |
| 2007 | -28.94% | -75.72% | 0.33x | 1.16x | $-100.87 Million |
| 2008 | -32.24% | -62.98% | 0.43x | 1.19x | $-84.35 Million |
| 2009 | 75.13% | 645.04% | 0.11x | 1.10x | $270.80 Million |
| 2010 | 3.94% | 10.20% | 0.35x | 1.12x | $-27.79 Million |
| 2011 | -1.71% | -6.50% | 0.23x | 1.16x | $-51.45 Million |
| 2012 | -12.60% | -35.79% | 0.31x | 1.14x | $-85.93 Million |
| 2013 | -21.90% | -70.50% | 0.28x | 1.12x | $-85.86 Million |
| 2014 | -10.29% | -19.15% | 0.48x | 1.13x | $-48.71 Million |
| 2015 | -17.22% | -26.85% | 0.54x | 1.18x | $-57.18 Million |
| 2016 | 14.01% | 24.58% | 0.50x | 1.13x | $10.11 Million |
| 2017 | -15.91% | -22.99% | 0.57x | 1.21x | $-56.51 Million |
| 2018 | -20.82% | -20.22% | 0.79x | 1.31x | $-54.34 Million |
| 2019 | 15.26% | 11.31% | 1.09x | 1.23x | $10.97 Million |
| 2020 | -4.41% | -8.73% | 0.33x | 1.53x | $-73.22 Million |
| 2021 | -6.15% | -8.57% | 0.46x | 1.57x | $-81.16 Million |
| 2022 | -15.53% | -18.28% | 0.55x | 1.55x | $-118.13 Million |
| 2023 | 0.20% | 0.20% | 0.70x | 1.47x | $-47.31 Million |
| 2024 | -0.96% | -0.92% | 0.71x | 1.48x | $-54.83 Million |
Industry Comparison
This section compares Photocure ASA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Photocure ASA (PHCUF) | $484.54 Million | -57.49% | 0.43x | $86.14 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |